Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

CAKIRCA, Mustafa; KARATOPRAK, Cumali; ZORLU, Mehmet; KISKAC, Muharrem; Kanat, MUSTAFA; CIKRIKCIOGLU, Mehmet; Soysal, Pinar; HURSITOGLU, Mehmet; CAMLI, Ahmet; ERKOC, Reha; ABDUL-GHANI, Muhammad

doi:10.2147/dddt.s52545

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

CAKIRCA M., KARATOPRAK C., ZORLU M., KISKAC M., Kanat M. , CIKRIKCIOGLU M. A. , ...More

DRUG DESIGN DEVELOPMENT AND THERAPY, vol.8, pp.239-243, 2014 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 8
Publication Date: 2014
Doi Number: 10.2147/dddt.s52545
Title of Journal : DRUG DESIGN DEVELOPMENT AND THERAPY
Page Numbers: pp.239-243
Keywords: asymmetric dimethylarginine (ADMA), dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, type 2 diabetes mellitus, GLUCAGON-LIKE PEPTIDE-1, MYOCARDIAL-INFARCTION, HEART-FAILURE, DYSFUNCTION, INHIBITION, RATS

Abstract

Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.